Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005812 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma
A Phase 2 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00005812 is a Phase 2 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00005812, a Phase 2 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have leptomeningeal metastases from a solid tumor or lymphoma.
Interventions
- DRUG temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-01 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005812
The ClinicalTrials.gov registry entry for NCT00005812 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.
NCT00005812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005812 about?
NCT00005812 is a clinical study titled "Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have leptomeningeal metastases from a solid tumor or lymphoma.
What is the current status of trial NCT00005812?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2000-01. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00005812?
The interventions under investigation include: temozolomide (DRUG).
Who is sponsoring clinical trial NCT00005812?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.